GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals,

   GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and
   Development Collaboration with Janssen Pharmaceuticals, Inc., to Develop
                        Multi-Valent Bacterial Vaccine

PR Newswire

ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013

ZURICH-SCHLIEREN, Switzerland, Jan. 4, 2013 /PRNewswire/ --GlycoVaxyn AG, a
leader in the development of innovative vaccines, today announced that Janssen
Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and
entered into a three-year research and development collaboration to develop a
multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation
technology.

"Bacterial pathogens that exist in multiple pathogenic strains pose
significant challenges for developing vaccines that target these strains,"
said Michael Wacker, co-founder and chief scientific officer of GlycoVaxyn.
"Our recombinant DNA-based vaccine technology is particularly well-suited for
polyvalent conjugate vaccines and should make the development and
commercialization of these vaccines more feasible and reliable."

GlycoVaxyn will collaborate with JPI's affiliate, Crucell Holland BV, on the
development of the multi-valent vaccine until proof-of-concept, after which
JPI will be responsible for later-stage clinical studies and world-wide
commercialization. The consideration to GlycoVaxyn includes an upfront
payment, milestone payments, royalties as well as reimbursement of research
and development expenses. Financial details of the agreement have not been
disclosed.

Philippe Dro, chief executive officer of GlycoVaxyn added, "This collaboration
is a further confirmation of the position GlycoVaxyn is about to occupy in the
vaccine development space. The whole team is dedicated to establish
GlycoVaxyn's technology as a powerful platform able to generate innovative
vaccine candidates. We are very pleased to work together with JPI and Crucell
and to be able to contribute to their vaccine development ambitions."

About GlycoVaxyn AG
GlycoVaxyn is a privately-funded company developing a portfolio of novel
bio-conjugate vaccines against common severe bacterial infections produced
with its unique, proprietary in vivo glycosylation platform. With this
platform, the company can develop and produce immunogenic glycoprotein
conjugates in a biological process that circumvents many of the challenges and
uncertainties involved in currently/chemical used methods. In addition to the
clinical stage Shigella vaccine, lead programs in preclinical stage are aimed
at the prevention of hospital acquired Staphylococcus aureus infections, as
well as pneumococcal invasive diseases and uropathogenic E. coli. GlycoVaxyn
is funded by a top-tier group of private investors including Sofinnova
Partners, Index Ventures and Edmond de Rothschild Investment Partners. For
further information, visit www.glycovaxyn.com.

Contacts:
                     Robert Flamm
GlycoVaxyn AG        Russo Partners, LLC
Tel: +41 44 733 8595 Tel: +1 212-845-4226
media@glycovaxyn.com robert.flamm@russopartnersllc.com



SOURCE GlycoVaxyn AG

Website: http://www.glycovaxyn.com
 
Press spacebar to pause and continue. Press esc to stop.